Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.
about
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cellsEpCAM (CD326) finding its role in cancerLesser-Known Molecules in Ovarian CarcinogenesisAntibody-based immunotherapy for ovarian cancer: where are we at?Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancerEpCAM in carcinogenesis: the good, the bad or the uglyActivator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cellsSystematic evaluation of candidate blood markers for detecting ovarian cancer.Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancerIntra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II studyHigh-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibodyIsolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysisRegulated intramembrane proteolysis and degradation of murine epithelial cell adhesion molecule mEpCAM.An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoPast, present and future targets for immunotherapy in ovarian cancerSystemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancerCoexpression of EpCAM, CD44 variant isoforms and claudin-7 in anaplastic thyroid carcinomaTROP-1/Ep-CAM and CD24 are potential candidates for ovarian cancer therapy.A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer.EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer.Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptorsA Recombinant Secondary Antibody Mimic as a Target-specific Signal Amplifier and an Antibody Immobilizer in ImmunoassaysEpithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineEpithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.Therapeutic targets and new directions for antibodies developed for ovarian cancer.Efficacy and feasibility of the epithelial cell adhesion molecule (EpCAM) immunomagnetic cell sorter for studies of DNA methylation in colorectal cancer.
P2860
Q21136080-638748FB-ACCC-4592-8F6D-BB7D44D66440Q24653692-66058E00-0046-4524-B886-E1CC34B54209Q26784533-614DEE52-8C7F-452A-BF9B-3B9E369B92E7Q27000514-D40BE9DA-815E-4684-B188-9CEE1A3C0975Q28235980-B4A05163-6ACF-4D1A-8135-DEB4B5DFCB79Q28293163-D690641F-136A-4199-B757-E3A1D4DD4E8EQ30427356-0D6A75D0-A7CB-4379-8510-45F78C22AA2AQ31149698-DD6B8E92-E074-4893-8382-0CFE2F9068F3Q33350146-3F77FEA3-63C4-4C88-93AB-8F6AFA16CC95Q33590557-6D832164-FF32-47A0-8508-A70D2197F6B2Q33755476-9F3C1350-DF1E-4A3D-AEDE-F70832B158EBQ33851325-25DA3778-6508-479E-A415-A4B36E18A064Q33917340-E0F4F805-5A4D-4E4F-858D-D2802B9E31BBQ34354529-B4BFA234-C708-45EC-9E47-48D63122C503Q34361383-D4B050D9-8F6B-4143-8F87-A49E120852CAQ34442318-D66DDB7B-A98C-4DBD-8C39-DC24345EDADEQ34570056-F98FC21E-C28F-42A4-97D5-9A21BA4964DDQ34934911-BAC5E4C6-0F7F-4CE2-B9E7-C42EA6611004Q34979489-46DF9765-D958-4DCB-A7E0-038D0DF47EC5Q34994161-9E78C2F1-1D68-443D-8A21-FAAF628C0877Q35007586-6F956053-E7C2-4F43-B04D-1957C66DDBEEQ35034010-365B897D-CADA-4B01-9DD0-F2F38F2B64C2Q35079157-801A1DB9-B016-4165-9E2B-D21DA86C0192Q35125662-C366AA9C-2DB7-44F5-8C47-7CFAB18D2FA9Q35146510-0C2CC192-20A5-4EF6-9579-A0A2E9030D0BQ35853937-90E1CFAE-831F-43A5-A9DA-1FC3D91E2991Q35936614-5AF01B54-D730-43FD-9BBE-2E2CE8E24B6CQ35960157-8DFAD45A-0F12-44C4-A5D2-B60E116D5631Q36544617-61E7C250-2841-4CBB-B7B1-50CD8178E79FQ36663666-EED11BFF-4428-4D91-93F8-B4AFA95DCEA0Q36775366-B1921C85-BEBA-40E5-A0CA-CF99309DB3CBQ36777139-BD44336D-051D-4FC3-A62C-8BE7C7CDB90CQ36785184-74FF968D-9E45-44EC-B74E-5064B45927C5Q36864520-B5A568F0-6B57-4A40-9580-20E62CF7030EQ36983909-DF175689-045C-4D79-849B-EEC14454203EQ37102182-AFDE6179-B996-4D05-95D8-F0AD2635A5CEQ37224420-B6A4FA63-5E8C-4B8E-9A12-4A4F07BABBD7Q37225693-AAB1A404-00A7-4700-96E6-BC503F0E03CCQ37397674-189618A6-B872-4B7A-AC4C-AA53DDE2A3F3Q37535389-E9FCD5BF-863E-4C03-8FC8-A4A22D53C237
P2860
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Overexpression of epithelial c ...... ith epithelial ovarian cancer.
@en
Overexpression of epithelial cell adhesion molecule
@nl
type
label
Overexpression of epithelial c ...... ith epithelial ovarian cancer.
@en
Overexpression of epithelial cell adhesion molecule
@nl
prefLabel
Overexpression of epithelial c ...... ith epithelial ovarian cancer.
@en
Overexpression of epithelial cell adhesion molecule
@nl
P2093
P1433
P1476
Overexpression of epithelial c ...... ith epithelial ovarian cancer.
@en
P2093
Alain G Zeimet
Christian Marth
Elisabeth Mueller-Holzner
Gilbert Spizzo
Guenther Gastl
Holger Moch
Patrick A Baeuerle
Peter Obrist
Philip Went
Stephan Dirnhofer
P304
P356
10.1016/J.YGYNO.2006.03.035
P407
P577
2006-05-06T00:00:00Z